What’s the latest funding news in the brain-computer interface market? (October 2026)
Every funding round, every investor, and who is really ahead in neurotech, in one document. Have a look ↓
Brain-computer interface funding remained active through October 2026, with the latest verified deals spanning ultrasound-based interfaces, cortical implants, EEG systems and dedicated neural-interface chips.
The 12 most recent qualifying financings include companies from the United States, China, the Netherlands, Australia and Japan, showing that BCI development is becoming increasingly global.
Clinical communication and rehabilitation remain important applications, but investors are also backing higher-bandwidth invasive systems, consumer EEG products and non-invasive ultrasound approaches.
And if you want to better understand this new industry, you can get our report on neurotech funding, valuations and who's ahead.
Insights
- At least roughly $420M was raised across the rounds where a reasonably precise dollar value was available, with Precision Neuroscience's $250M Series D representing well over half of that measurable capital.
- China accounted for seven of the 12 latest brain-computer interface funding deals, highlighting how quickly the country's invasive, EEG and ultrasound BCI ecosystem has expanded in 2026.
- Ultrasound has become a meaningful alternative BCI architecture: Bridge Neurotech, BCI-Sonics and Gestala all raised capital around non-invasive systems that aim to access brain activity without implanted electrodes.
- The funding range is unusually wide, from UCANACT's sub-$1M pre-seed round to Precision Neuroscience's $250M Series D, showing that the BCI market now includes both university spinouts and commercialization-stage platforms.
- Medical applications still dominate the latest BCI funding activity, particularly communication restoration, movement rehabilitation, visual restoration and device control for patients with severe neurological impairment.
- Dedicated BCI hardware remains investable on its own: All-Brain Chip, Active Technology, Xinsheng Shijie and Neuralicorn are building neural chips, electrodes or integrated implant systems rather than general-purpose neurotechnology.
- The latest rounds also show a split between invasive systems seeking higher signal quality and non-invasive systems seeking easier deployment, with substantial capital flowing to both technical approaches.
- Several of the youngest companies raised unusually large rounds before broad commercialization, suggesting investors are financing expensive BCI engineering, manufacturing and clinical work much earlier than in conventional software markets.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
Summary table of the latest funding deals in the brain-computer interface market as of October 2026
We define the brain-computer interface market as systems that translate brain activity into commands or feedback for an external device.
We include invasive and non-invasive brain interfaces, neural decoding software and dedicated interface hardware for clinical, research or consumer use.
We exclude general brain imaging, muscle-controlled interfaces and neurostimulation without a brain-signal interface.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Bridge Neurotech | October 6, 2026 | $13.5M | Early-stage financing | Non-invasive ultrasound BCI & Neural decoding |
| Precision Neuroscience | September 24, 2026 | $250M | Series D | Minimally invasive cortical BCI & Assistive device control |
| BCI-Sonics | September 22, 2026 | ~$28M | Pre-A | Non-invasive ultrasound BCI & Closed-loop neural decoding |
| UCANACT | September 15, 2026 | ~$0.92M | Pre-seed | Assistive communication BCI & Brain-to-speech |
| All-Brain Chip | August 28, 2026 | Multi-$M | Angel | Invasive BCI hardware & High-density neural interfaces |
| Active Technology | August 3, 2026 | ~$46M | Angel | Implantable BCI & Neural-interface hardware |
| Pengnao Technology | July 14, 2026 | ≥$1.4M | Strategic | EEG BCI & Consumer and rehabilitation interfaces |
| Gestala | July 3, 2026 | ~$62M | Angel+ | Non-invasive ultrasound BCI & Brain sensing |
| Fluent BCI | June 29, 2026 | ~$1.3M | Pre-seed | Speech-decoding BCI & Assistive communication |
| Xinsheng Shijie | June 17, 2026 | ~$14M | Seed | Invasive BCI & Visual and language decoding |
| LIFESCAPES | June 15, 2026 | ~$3.7M-$4.1M | Undisclosed equity round | EEG motor rehabilitation BCI & Clinical neurorehabilitation |
| Neuralicorn / Xihu Lingxi | June 8, 2026 | Several $M | Angel+ | Implantable BCI chips & Language decoding |
All the latest funding deals in the brain-computer interface market as of October 2026
Bridge Neurotech raised $13.5M in October 2026 to develop its non-invasive ultrasound brain interface.
When was it?
Bridge Neurotech announced the financing on October 6, 2026, alongside the company's public launch.
Who are they?
Bridge Neurotech is building a wearable system that uses ultrasound to sense brain activity through the skull and AI to turn those signals into useful information and commands.
Geographical focus?
Bridge Neurotech is based in Silicon Valley and is beginning human research in Redwood City, California, while targeting broader medical and consumer applications.
Why do we include them in the brain-computer interface market?
Bridge Neurotech belongs in the non-invasive BCI and neural-decoding category because its system is designed to sense brain activity and ultimately translate it into a functional interface.
What is the company stage?
Bridge Neurotech is at an early research and human-validation stage, with its first study currently enrolling rather than a commercial product already on the market.
How much did they raise?
Bridge Neurotech raised $13.5M in this financing.
What round is it?
Bridge Neurotech did not disclose a conventional seed or Series round label, so the deal is best classified as early-stage launch financing.
Why did they raise?
Bridge Neurotech raised the capital to advance transcranial ultrasound sensing, neural decoding and human validation of its wearable BCI approach.
This is just a preview page. Don’t worry if a number looks old: the report gets refreshed, and you’ll always get the latest version.
Precision Neuroscience raised $250M in September 2026 as its cortical BCI moved closer to commercialization.
When was it?
Precision Neuroscience announced the Series D on September 24, 2026.
Who are they?
Precision Neuroscience develops the Layer 7 Cortical Interface, a thin high-density electrode array designed to record neural activity and let people with severe impairment control digital devices.
Geographical focus?
Precision Neuroscience is U.S.-based and works across a large American clinical network, with longer-term ambitions for broader commercialization.
Why do we include them in the brain-computer interface market?
Precision Neuroscience is a direct minimally invasive cortical BCI company because Layer 7 records brain signals and decodes intended movement for external device control.
What is the company stage?
Precision Neuroscience is at a late clinical and early commercialization stage, with more than 100 patient procedures, FDA clearance for temporary use and a growing hospital network.
How much did they raise?
Precision Neuroscience raised $250M in the Series D, bringing total capital raised to about $430M.
What round is it?
Precision Neuroscience raised an oversubscribed Series D.
Why did they raise?
Precision Neuroscience raised the capital to expand clinical programs, advance further FDA work and build infrastructure for commercialization.
BCI-Sonics raised about $28M in September 2026 for its non-invasive ultrasound BCI platform.
When was it?
BCI-Sonics announced the financing on September 22, 2026.
Who are they?
BCI-Sonics, also known as Huachao Shenkong, combines focused ultrasound, multimodal brain sensing and AI neural decoding to build closed-loop brain interfaces.
Geographical focus?
BCI-Sonics is headquartered in Shanghai and is initially developing its research, clinical and technology products for the Chinese market.
Why do we include them in the brain-computer interface market?
BCI-Sonics belongs in the non-invasive closed-loop BCI category because the platform reads brain signals, uses AI for neural decoding and adjusts its interaction using real-time feedback.
What is the company stage?
BCI-Sonics is at an advanced prototype and preclinical-to-early-clinical stage, with two product generations developed and clinical work planned.
How much did they raise?
BCI-Sonics raised RMB200M, approximately $28M.
What round is it?
BCI-Sonics raised a Pre-A round.
Why did they raise?
BCI-Sonics raised the capital for product development, specialist hiring, clinical research and expansion of its AI infrastructure.
UCANACT raised about $0.92M in September 2026 to commercialize assistive brain-to-speech technology.
When was it?
UCANACT announced the financing on September 15, 2026.
Who are they?
UCANACT is developing a brain-computer interface that translates neural activity into computer actions and speech for people with severe motor disabilities.
Geographical focus?
UCANACT is based in Utrecht in the Netherlands and is initially translating research from UMC Utrecht into a practical assistive communication product.
Why do we include them in the brain-computer interface market?
UCANACT belongs in the assistive communication BCI category because its core product converts brain signals directly into digital commands and speech.
What is the company stage?
UCANACT is at the pre-seed and translational prototype stage, moving academic BCI technology toward independent home use.
How much did they raise?
UCANACT raised €800,000, approximately $0.92M.
What round is it?
UCANACT raised a pre-seed round.
Why did they raise?
UCANACT raised the capital to productize the system, automate training and calibration, and make the technology easier for patients to use outside specialist laboratories.
All-Brain Chip raised a multi-million-dollar angel round in August 2026 for high-density invasive BCI hardware.
When was it?
All-Brain Chip announced the angel financing on August 28, 2026.
Who are they?
All-Brain Chip is a Shanghai startup developing flexible silicon CMOS neural-interface arrays with as many as 64,000 channels and integrated signal amplification.
Geographical focus?
All-Brain Chip is based in Shanghai and is initially commercializing research developed within China's BCI and flexible-electronics ecosystem.
Why do we include them in the brain-computer interface market?
All-Brain Chip belongs in the invasive BCI hardware category because its core product is a high-density electronic interface built specifically to acquire neural signals from the brain.
What is the company stage?
All-Brain Chip is at a very early preclinical and technology-commercialization stage, having been established in August 2026.
How much did they raise?
All-Brain Chip disclosed an angel financing of tens of millions of RMB, which represents a multi-million-dollar round.
What round is it?
All-Brain Chip raised an angel round.
Why did they raise?
All-Brain Chip raised the financing to industrialize its flexible CMOS neural-interface technology and move the platform from academic research toward implantable products.
Active Technology raised about $46M in August 2026 for its implantable brain-computer interface platform.
When was it?
Active Technology announced the financing on August 3, 2026.
Who are they?
Active Technology develops a full-stack invasive BCI system spanning flexible electrodes, dedicated neural chips, wireless systems and AI-based brain-signal decoding.
Geographical focus?
Active Technology is headquartered in Shanghai and is initially focused on clinical applications in China across movement, language, vision and neurological conditions.
Why do we include them in the brain-computer interface market?
Active Technology is a direct implantable BCI pure player because its technology records neural activity and converts those signals into useful outputs through dedicated hardware and decoding algorithms.
What is the company stage?
Active Technology is at a preclinical and early clinical-translation stage, with prototype systems developed and work progressing toward patient applications.
How much did they raise?
Active Technology raised RMB330M, approximately $46M.
What round is it?
Active Technology raised an angel round.
Why did they raise?
Active Technology raised the financing to advance clinical trials, expand its facilities, grow the team and continue development of its invasive neural-interface platform.
Pengnao Technology raised at least $1.4M in July 2026 to expand its commercial EEG brain interfaces.
When was it?
Pengnao Technology announced the strategic financing on July 14, 2026.
Who are they?
Pengnao Technology develops EEG-based brain-computer interfaces for cognitive rehabilitation, attention, sleep, consumer use and vehicle applications.
Geographical focus?
Pengnao Technology is based in Shenzhen and is initially focused on China through healthcare, consumer, institutional, elder-care and automotive channels.
Why do we include them in the brain-computer interface market?
Pengnao Technology belongs in the non-invasive EEG BCI category because real-time brain-signal decoding and closed-loop feedback are central to its products.
What is the company stage?
Pengnao Technology is at an early commercial and growth stage, with hardware production, clinical translation and product distribution already underway.
How much did they raise?
Pengnao Technology disclosed financing of at least RMB10M, or roughly $1.4M, with reports describing the total as tens of millions of RMB.
What round is it?
Pengnao Technology raised a strategic financing round.
Why did they raise?
Pengnao Technology raised the capital to strengthen EEG algorithms, pursue medical-device certification, expand vehicle applications, increase production and grow distribution.
Gestala raised about $62M in July 2026 to scale its non-invasive ultrasound BCI technology.
When was it?
Gestala announced the financing on July 3, 2026.
Who are they?
Gestala is developing ultrasound-based brain-computer interfaces designed to sense and interact with broad and deep regions of the brain without implanted electrodes.
Geographical focus?
Gestala operates from China, including Shanghai and Chengdu, while developing technology with broader medical and international ambitions.
Why do we include them in the brain-computer interface market?
Gestala belongs in the non-invasive ultrasound BCI category because its platform combines brain sensing, signal analysis and ultrasound-based interaction as an alternative to implanted electrodes.
What is the company stage?
Gestala is at an angel-stage technology and product-development phase, while simultaneously building engineering, manufacturing and clinical capabilities.
How much did they raise?
Gestala raised RMB420M, approximately $62M.
What round is it?
Gestala raised an Angel+ round.
Why did they raise?
Gestala raised the capital to advance core ultrasound BCI technology, expand intellectual property, engineer production-ready products, build manufacturing capacity and broaden clinical applications.
Fluent BCI raised about $1.3M in June 2026 to advance its intended-speech decoding interface.
When was it?
Fluent BCI's A$2M financing was announced at the end of June and reported publicly on July 1, 2026.
Who are they?
Fluent BCI is developing InScribe, a sub-scalp electrode system that captures speech-related neural activity and uses AI to translate intended speech into text.
Geographical focus?
Fluent BCI is based in Melbourne and is initially preparing clinical work in Australia before targeting the broader assistive-communication market.
Why do we include them in the brain-computer interface market?
Fluent BCI belongs in the speech-decoding and assistive communication BCI category because the system directly converts neural activity associated with intended speech into digital output.
What is the company stage?
Fluent BCI is at a pre-seed and preclinical stage, with the company preparing for first-in-human studies.
How much did they raise?
Fluent BCI raised A$2M, approximately $1.3M.
What round is it?
Fluent BCI raised a pre-seed round.
Why did they raise?
Fluent BCI raised the capital to grow its engineering team, complete regulatory work and prepare the InScribe interface for first-in-human testing.
Xinsheng Shijie raised about $14M in June 2026 for high-channel invasive BCI technology.
When was it?
Xinsheng Shijie announced the financing on June 17, 2026.
Who are they?
Xinsheng Shijie is a Beijing startup developing high-channel-count invasive BCI chips, fully implanted neural-interface hardware and decoding algorithms for applications including visual restoration and communication.
Geographical focus?
Xinsheng Shijie is based in Beijing and is initially pursuing clinical development and commercialization within China's BCI ecosystem.
Why do we include them in the brain-computer interface market?
Xinsheng Shijie belongs in the invasive BCI and neural-decoding category because its system combines implanted neural-signal acquisition with algorithms designed to reconstruct visual and language information.
What is the company stage?
Xinsheng Shijie is at a seed and preclinical stage, with work focused on neural chips, prototype development, animal studies and its first clinical applications.
How much did they raise?
Xinsheng Shijie raised nearly RMB100M, approximately $14M.
What round is it?
Xinsheng Shijie raised a seed round.
Why did they raise?
Xinsheng Shijie raised the financing for neural-chip validation, prototype development, animal testing, clinical preparation and team expansion.
LIFESCAPES raised roughly $4M in June 2026 to expand its EEG rehabilitation BCI internationally.
When was it?
LIFESCAPES announced the financing on June 15, 2026.
Who are they?
LIFESCAPES develops EEG-based brain-machine interfaces that detect a stroke patient's intention to move and activate rehabilitation equipment or feedback systems.
Geographical focus?
LIFESCAPES is based in Japan and is expanding internationally, with particular attention to Malaysia and the wider ASEAN region as well as North America.
Why do we include them in the brain-computer interface market?
LIFESCAPES belongs in the non-invasive motor-rehabilitation BCI category because its technology reads brain activity associated with movement intent and translates it into external rehabilitation actions.
What is the company stage?
LIFESCAPES is at a clinical and early commercial growth stage, with an existing BMI product used in Japan and a next-generation therapeutic system in development.
How much did they raise?
LIFESCAPES raised ¥600M, approximately $3.7M to $4.1M depending on the exchange rate used.
What round is it?
LIFESCAPES did not disclose a conventional Series label and described the financing as an equity capital raise.
Why did they raise?
LIFESCAPES raised the capital to advance clinical trials, expand overseas commercialization and develop partnerships in ASEAN and North America.
This is a preview page. Spotted an outdated number? That’s normal here. The report you get is always the freshest version.
Neuralicorn raised several million dollars in June 2026 to commercialize BCI chips and Mandarin neural decoding.
When was it?
Neuralicorn announced the financing on June 8, 2026.
Who are they?
Neuralicorn, also known as Xihu Lingxi, develops implantable BCI chips, integrated neural-interface hardware and algorithms for decoding language and other brain signals.
Geographical focus?
Neuralicorn is based in China and grew from research connected with Westlake University, with an early emphasis on Mandarin-language neural decoding.
Why do we include them in the brain-computer interface market?
Neuralicorn belongs in the invasive BCI hardware and neural-decoding category because its core technology captures brain signals and converts them into language and other usable outputs.
What is the company stage?
Neuralicorn is at an Angel+ and preclinical commercialization stage, moving its neural-interface chips and decoding research toward product and clinical applications.
How much did they raise?
Neuralicorn disclosed an Angel+ round worth tens of millions of RMB, equivalent to several million U.S. dollars.
What round is it?
Neuralicorn raised an Angel+ round.
Why did they raise?
Neuralicorn raised the financing to industrialize its BCI chips and Mandarin neural-decoding technology while advancing product development and clinical translation.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
